Pre-launch19:59 CET
hansa/indexSubscribe

launch · IS · 21 AUG 2026

Alvotech has entered a partnership with Lotus Pharmaceutical to market two biosimilars in the U.S. and Asia, potentially generating up to $150 million in licensing revenue.

Alvotech · EUR 128.2M

Provenance

Sources

  1. Viðskiptablaðið · 21 Aug 2026

    Allt að 18 milljarðar í leyfistekjur af samningi við Lotus

    „Í fyrsta sinn munum við markaðssetja sjálf lyf þróuð af Alvotech í Bandaríkjunum,” segir forstjóri Alvotech.